Safety
ADVERSE EVENTS
A total of 25 patients were included in safety analysis (Table Treatment‐related adverse events of all grades in pyrotinib monotherapy part.
Treatment‐related adverse events of all grades in pyrotinib combined with docetaxel part.In the combination with docetaxel part, for no DLT observation of pyrotinib alone at dose level of 240 mg and occurrence of effective case (